Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies has reported that it is implementing an organizational development and growth plan to address changes resulting from the acquisition of DDP Therapeutics and anticipated increases in business activity.
Subscribe to our email newsletter
Wayne Danter, president and chief scientific officer of Critical Outcome Technologies (COTI), said: “Over the last 12 months COTI has made considerable progress in advancing our product pipeline and developing important industry relationships. Our proprietary technology Chemsas and our novel small molecules have been well-received by prospective partners. In the next 12 to 18 months we anticipate increased business activity, as we further develop key relationships via profitable collaborations, including our Merck Serono pilot project, additional pilot projects with other pharmaceutical organizations and the potential out-licensing of lead compounds from the small cell lung cancer (SCLC) library recently acquired from DDP Therapeutics (DDP).”
The company also announced that Scott Baker has left COTI to pursue a leadership position within the branded pharmaceutical industry. Mr Baker served as COTI’s COO since April 1, 2007 with a focus on supporting DDP on behalf of COTI in the development of the SCLC library and the acquisition of DDP.
Critical Outcome Technologies has temporarily assigned Mr Baker’s areas of responsibility to Dr Danter, pending the addition of new staff consistent with the implementation of its evolving organizational strategy.